Free Trial
TSE:CRON

Cronos Group Q3 2025 Earnings Report

Cronos Group logo
C$3.76 0.00 (0.00%)
As of 06/12/2026 04:00 PM Eastern

Cronos Group EPS Results

Actual EPS
C$0.07
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Cronos Group Revenue Results

Actual Revenue
$50.60 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cronos Group Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Cronos Group Earnings Headlines

Cronos Group Q1 earnings preview
Read this warning immediately
Porter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel
See More Cronos Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cronos Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cronos Group and other key companies, straight to your email.

About Cronos Group

Cronos Group (TSE:CRON), headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.

View Cronos Group Profile